Affimed NV named Leila Alland as its chief medical officer, effective March 26.

Alland was most recently the chief medical officer of Tarveda Therapeutics Inc., a Watertown, Mass.-based developer of drug candidates that target solid tumors.

Prior to joining Tarveda, she was with AstraZeneca PLC as vice president and head of oncology for early clinical development.

Germany-based Affimed works to discover and develop cancer immunotherapies.